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ABSTRACT
Objectives: The aim of the study was to assess the level of implementation of recommendations of the Ministry of Health 
regarding infectious disease screening during pregnancy.
Material and methods: The study included 477 patients who were admitted to the delivery room between December 
2015 and February 2016. Data on screening test results were collected based on medical records covering the period 
before the admission.
Results: The Human Immunodeficiency Virus (HIV) screening was conducted in 410 (86%). 460 (96%) of patients were 
screened for Hepatitis B Virus (HBV) and 427 (89.5%) for Hepatitis C Virus (HCV). Syphilis screening covered 465 (97.5%) of 
patients. Immunoglobulin M (IgM) titer against Rubella Virus (RV) was assessed in 218 (45%) patients and immunoglobulin G 
(IgG) in 319 (66.9%). Screening for Toxoplasma gondii based on assessment of IgM titer was conducted in 440 (92%) patients 
while IgG titter was assessed in 413 (86.6%). 343 (71.9%) patients had obtained vaginal swabs for Group B Streptococci (GBS) 
while the anal swabs were taken only from 268 (56.2%) patients.
Conclusions: Coverage of screening for syphilis and HBV was similar to the countries with highest prevalence of conducting 
such screening, on the other hand RV screening place as among countries with lowest prevalence. There is an increasing 
trend in conducting HIV screening. Screening for HCV and toxoplasmosis is at satisfactory level and Poland is one of a few 
European countries offering such screening. The screening for GBS is insufficient which result in excessive use of intrapar-
tum antibiotic prophylaxis.
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INTRODUCTION
The recommendation regarding the antenatal care is-
sued by the Minister of Health of Poland on 20 Septem-
ber 2012 specifies the standards of care for the pregnant 
women during physiological pregnancy, childbirth and 
postpartum period. An important part of the guidelines 
are recommendations for the screening of pregnant women 
for certain infectious diseases that may constitute a threat 
to the physiological course of pregnancy or to the foetus [1]. 
According to the guidelines, every pregnant women up to 
10th weeks of pregnancy should have been screened for 
Human Immunodeficiency Virus (HIV), Treponema pallidum 
infection that causes syphilis and Hepatitis C Virus (HCV). 
Moreover the immunoglobulin M (IgM) and immunoglobu-
lin G (IgG) titer against the Rubella Virus (RV) and Toxoplasma 
gondii (T. gondii) should be determined (in case of a negative 
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results, the test for T. gondii should be repeated between 
21st and 26th weeks of gestation). Between 33rd and 37th 
weeks of gestation the Hepatitis B Virus (HBV) screening 
should be carried out as well as vagina and anal swabs for 
the Streptococcus agalactiae which are classified by Lance-
field classification as a Group B Streptococci (GBS) [1]. Ad-
ditionally the HIV screening should be repeated, and among 
patients with an increased population or individual risk the 
tests for T. pallidum and HCV as well [1]. The establishing of 
nationwide guidelines for the Polish population is part of 
a pan-European trend aimed at reducing the incidence of 
mother-to-child transmission (MTCT) and congenital syn-
dromes. The report prepared by the European Centre for 
Disease Prevention and Control (ECDC) compares the indi-
vidual EU member states recommendation for the infectious 
disease screening during pregnancy as well as the degree 
of their implementation. Out of 26 countries including Po-
land, 25 (except for Hungary) has national guidelines on the 
screening of pregnant women for infectious diseases [2]. 
Recommendations for specific infection diseases covered 
by the guidelines as well as to the time and manner of 
conducting the screening differ between countries. Testing 
for syphilis is recommended in all the countries included in 
the survey, while HIV testing is recommended in 24 coun-
tries (except for Hungary and Slovenia), HBV screening in 
23 countries (except Lithuania, Norway and Romania), and 
RV screening in 17 countries (except for Denmark, Estonia, 
Finland, Hungary, Lithuania, Latvia, the Netherlands, Ro-
mania and Slovenia) [2]. The report prepared by the ECDC 
did not cover the screening tests policies for HCV, T. gondii 
and GBS [2].
OBJECTIVES
The aim of the study was to assess the level of imple-
mentation of recommendations of the Ministry of Health 
regarding infectious disease screening during pregnancy [1]. 
So far, there were no overall assessment conducted for the 
Polish population. 
MATERIAL AND METHODS
The study included patients who were admitted to the 
delivery room of the third level perinatal center between 
December 2015 and February 2016. On a given period of 
time we collect the data from 477 patients. Antenatal in-
fectious diseases screening in Poland is mainly held by the 
out-patient services but all the obtained results should be 
properly noted in the Personal Maternity Record. Moreover 
patients had the original laboratory results as a part of their 
own medical records. Patients are free to choose provider 
where the tests are conducted thus in our research the 
specific laboratory characteristics of the single tests are 
lacking. In our research we studied the Personal Maternity 
Records and all the lab test results that patients bring to the 
admission room in search of the laboratory results. Data on 
screening test results cover the period before the admission 
to the delivery room and if the patient did not have the 
result of any of the recommended screening tests, the test 
was commissioned during hospital admission, but the result 
was not taken into account in the present study.
RESULTS
Taking into account that we included all the patients 
admitted to the delivery room between studied period 
there were no important differences in baseline character-
istics (age, education status, number of pregnancies and 
place of living) between the groups of patients who had or 
had not the screening  test results. 410 (86%) patients had 
at least once during pregnancy performed tests for HIV, 
all the results were negative. The HBV screening was per-
formed in 460 (96%) patients with 4 positive results, while 
for HCV 427 (89.5%) patients were tested with 2 positive 
results. Screening for syphilis which included 465 (97.5%) 
patients and resulting in only negative results was the most 
often performed test in our research. In turn, the least likely 
performed test was the IgM titer against the RV, which was 
performed in 218 (45%) patients with 2 positive results. The 
IgG titer against RV was determined in 319 (66.9%) patients, 
and the majority of them — 301 (94%) had reached protec-
tive antibody levels. IgM against Toxoplasma gondii was 
determined in 440 (92%) patients of whom 3 had positive 
results, while IgG titer was assessed in 413 (86.6%) patients 
and give mostly negative result — 330 (80%). 343 (71.9%) 
patients had the vaginal swab for GBS obtained, but the 
rectal swabs were collected only from 268 (56.2%) pa-
tients. 131 (27.5%) patients admitted to the delivery rooms 
did not have any swabs taken during the pregnancy. Vaginal 
swabs were positive in 85 (25%) patients, and rectal swabs 
in 68 (25.4%). 192 (40%) patients had both swabs negative.
DISCUSSION
The report prepared by the ECDC declare that among 
the 18 countries that provided information on the preva-
lence of screening for HIV during pregnancy, the majority 
(12/18) reported a 95% or a higher percentage of patients 
who had performed test at least once during the pregnancy. 
The Polish data provided for the ECDC report came from 
the document prepared by the Team for Implementation 
of the National Program for Prevention of HIV and Com-
bating AIDS in Mazowieckie [3]. Based on health records 
of 1111 pregnant women included in the survey, the test 
for HIV were not performed in 370 (33.3% ) patients [3]. In 
our group, the percentage of women who did not have 
screening for HIV during pregnancy was 14%. Despite sig-
nificant improvements in testing for HIV during pregnancy 
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in relation to the data presented in the report from 2013, 
Poland compared to other European Union countries still 
has a much lower percentage of patients undergoing the 
screening. Mother-to-child transmission (MTCT) is the major 
cause of HIV infection among children [4]. It should be noted 
that, according to the data from Polish National Institute of 
Public Health only in 2015 there were 184 women newly 
diagnosed with HIV mostly in reproductive age — 158 pa-
tients (86%) between the age 15 to 49 [5]. In addition, in 
2015 the HIV infection occurred in 5 newborns which clearly 
shows the gaps in the screening [5]. Detection of the virus 
during pregnancy allows the patient to undergo an ap-
propriated treatment. Reduction of the viral load below 
50 copies/mL, implementation of highly active antiretroviral 
therapy and the abandonment of breastfeeding reduces the 
risk of vertical transmission to 1–2% [6]. Those goals could 
be only achieved when the positive serological status of the 
pregnant women is known during the pregnancy. Modern 
HIV screening is based on the IIIrd and IVth generation test 
that detect the antibodies or antibodies and p24 antigen 
of the HIV. 
HBV screening is carried out in 23 European Union coun-
tries covered by the ECDC report except Lithuania, Romania 
and Norway. In most countries, including Poland screening is 
based on detection of Hepatitis B surface antigen — HBsAg [2]. 
Poland did not have data on the prevalence of screening for 
the presence of HBsAg, however, among the 13 countries 
that provided such data 8 determined the prevalence of 
screening at a level exceeding 95% [2]. In the presented 
results the determination of HBsAg was performed in 96% of 
patients, which places our studied population among coun-
tries with a high percentage of patients who were screened 
for HBV. The risk of vertical transmission depends on the 
serological status of the pregnant woman infected with HBV. 
It is highest in the presence of HBsAg and HBeAg antigen 
in the blood — 70–90%, while the presence of only HBsAg 
reduce the risk of vertical transmission to 15% [7, 8]. Due 
to the fact that there is a high risk of vertical transmission it 
is necessary to conduct screening for HBV infection among 
pregnant women, because it enables the implementation of 
appropriate treatment for newborn which largely prevents 
the infection in the chronic form. The only available method 
of prevention of neonatal infection is the administration of 
the vaccine and specific immunoglobulin. The effectiveness 
of such treatment is estimated at 90% [9]. 
ECDC report does not include data on the screening for 
HCV in the population of pregnant patients. There is also lack 
of extensive research on the prevalence of HCV infection in 
the population of pregnant patients in Poland. Aniszewska 
et al. in their work evaluated the prevalence of HCV in the 
population of 544 pregnant women at 2.02% [10]. So far 
there are no data on the prevalence of screening for HCV in 
the population of pregnant women, which is recommended 
by the Minister of Health [1]. In the population of patients 
included in our research HCV screening was commissioned 
in 427 (89%) patients, giving 2 (0.5%) positive results. Vertical 
transmission is the most common route of transmission of 
HCV in the population of infants and children. The risk of 
transmission of virus is estimated to be 1.8–5% [11]. Cur-
rently there is no treatment options for women infected 
with HCV during pregnancy because all the schemes are 
based on ribavirin, which has a strong teratogenic effect. 
Therefore, current screening for HCV in the population of 
pregnant patients aims at selecting a group of patients 
Table 1. Number of patients covered by the screening with the results
Number (%) of patiend 
undergoing screening Number (%) of negative results Number (%) of positive results
HIV 410 (86%) 410 (100%) 0 
HBV 460 (96%) 456 (99%) 4 (1%)
HCV 427 (89.5%) 425 (99.5%) 2 (0.5%)
Syphilis 465 (97.5%) 465 (100%) 0
Rubella Virus
IgM 218 (45%) 216 (99%) 2 (1%)
IgG 319 (66.9%) 18 (6%) 301 (94%)
Toxoplasma gondii
IgM 440 (92%) 437 (99.3%) 3 (0.7%)
IgG 413 (86.6%) 330 (80%) 83 (20%)
S. agalactiae
Vaginal swab 343 (71.9%) 258 (75%) 85 (25%)
Anal swab 268 (56.2%) 200 (74.6%) 68 (25.4%)
HIV — Human Immunodeficiency Virus; HBV — Hepatitis B Virus; HCV — Hepatitis C Virus
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infected with the virus so it would be possible to provide 
specialised neonatal care for their children.
T. pallidum is a Gram-negative bacteria which is the 
etiological agent of syphilis. The risk of vertical transmission 
largely depends on the viral load, and thus the stage of the 
disease. In the case of early syphilis risk of foetal infection 
range from 70% to 100%, early latent syphilis — 40%, and late 
syphilis — 10% [8]. The most effective antibiotic treatment 
of syphilis is penicillin, which can be successfully used also 
during pregnancy. Effective treatment of syphilis using peni-
cillin reduces the risk of vertical transmission to 1–2% [12], 
thus the screening allows us to select pregnant patients 
with syphilis and treat them during pregnancy which results 
in better maternal and neonatal outcomes but also breaks 
the transmission route. Untreated syphilis in pregnancy 
may cause intrauterine foetal death or miscarriage and the 
birth of a living child may result in the occurrence of early 
or late congenital syphilis [8]. The report prepared by the 
ECDC acclaims that test for syphilis during pregnancy is 
recommended in all countries, but data on its course and 
results were provided only by the 24 countries, except for 
Portugal and Poland [2]. In Poland, the screening is based on 
the Venereal Disease Research Laboratory (VDRL) test, which 
is a non-treponemal test, so every positive result requires 
confirmation with the treponemal test [13]. For the 18 coun-
tries that provided information on the extent of screening 
14 has determined that the test for syphilis was performed 
at least once during pregnancy in 95% of patients [2]. 
In our population the screening for syphilis was the most 
often ordered test and covered 465 (97.5%) patients, while 
giving only negative results.
The last screening test evaluated in the report prepared 
by the ECDC was a test assessing the immunisation of the 
population of pregnant patients against RV. Serological 
screening for presence of antibodies against RV is recom-
mended in 14/26 countries participating in the report. 
There is no data on the percentage of women covered 
by the screening. According to Polish recommendations, 
each pregnant woman should have checked the IgM titer, 
which testify to the fresh or recent infection and IgG titer, 
which testify to the past illness or vaccination and provide 
durable resistance [1, 8]. This enables the identification of 
a group of patients who are not immune to RV infection 
during pregnancy. Having data on the serological status 
of patients in the early stages of pregnancy also allows 
more accurate interpretations of repeated serological tests 
performed in the case of contact with RV during later stage 
of pregnancy. Infection before 16 weeks of gestation is as-
sociated with the risk of congenital rubella syndrome, which 
is characterised by sensorineural deafness, eye abnormali-
ties and congenital heart disease (Gregg triad) [14]. In the 
studied population the IgM were identified in 218 (45%) 
patients, and IgG in 319 (66.9%) patients. Serological test 
for RV was the least likely performed screening among 
pregnant patients. The percentage of patients who had 
positive titer of IgG and so were immune against RV was 
94% (301). The paper by Janaszek-Seydlitz et al. published 
in 2003 assessed 1.289 samples of blood from women aged 
15–30 from 6 provinces of Poland for presence of IgG against 
rubella with 89.5% of positive results, which is similar to that 
obtained in our research [15].
T. gondii infection occurs mostly through the consump-
tion of raw meat containing cysts or unwashed vegetables 
or fruits contaminated with oocysts which are the result of 
sexual reproduction of the parasite in cats [16]. Infection 
during pregnancy carries a risk of miscarriage as well as the 
development of defects affecting the nervous system and 
eyes [17]. Diagnosis of T. gondii infection during pregnancy 
only on the basis of clinical signs is extremely difficult be-
cause 90% of infections are asymptomatic [18] and therefore 
an important point in the prevention of congenital toxo-
plasmosis is screening based on a determination of IgM and 
IgG titer. In the study population 440 (92%) patients were 
evaluated for IgM titer of which 99.3% were negative. The 
IgG titer were determined in 413 (86.6%) patients in whom 
80% of the results were negative, and thus this group of pa-
tients had no previous contact with the parasite which forms 
a risk for the development of infection during pregnancy. 
The paper by Nowakowska et al. published in 2006 shows 
that in population of 4916 patients aged 19-46 enrolled to 
the study between 1998 and 2003, only 41.3% had positive 
antibody IgG titer against T. gondii [19]. Our work has shown 
that the observable trend is to further reduce the number 
of pregnant patients who had have contact with T. gondii 
in favour of patients susceptible to the development of 
infection during pregnancy.
Streptococcus agalactiae is the Gramm-positive bacte-
ria that physiologically colonise the lower gastrointestinal 
tract and the genitourinary system. S. agalactiae colonisa-
tion of the neonate during delivery, which occurs in 70% of 
cases, may result in the development of lower respiratory 
tract infections, sepsis and meningitis. It is estimated that 
mortality due to S. agalactiae infections among newborns 
is up to 20% [20]. The use of an appropriate intrapartum 
antibiotic prophylaxis based on penicillin G or ampicillin 
reduces the risk of the disease in newborn. Screening for 
GBS is based on the vaginal and anal swabs. In the case 
of any positive result, or lack of the screening the patient 
requires the implementation of intrapartum antibiotic 
prophylaxis. Testing for GBS colonisation during pregnancy 
is particularly important not only because of the possibility 
of effective intrapartum antibiotic prophylaxis, but also 
because of the possibility to avoiding it, when both swabs 
from are negative [21]. In the study 343 (71.9%) patients 
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had obtained vaginal swab, while rectal swab were taken 
only in 268 (56.2%) patients. 131 (27.5%) patients had not 
taken any of the swabs, which implicates the need to use 
antibiotics. Based on the vaginal swabs the colonisation 
is estimated at 25% in turn, rectal colonisation occurs in 
25.4% of patients. A study conducted between 2001 and 
2002 at the Department of Obstetrics and Gynaecology 
Institute of Mother and Child in Warsaw showed that in 
a group of 1.678 pregnant women the presence of group 
B streptococci were found in 331 (19.7%) patients [22]. 
On the other hand, a study conducted by the Brzychczy-
-Włoch et al. showed that in 2004–2005 colonisation of 
women with normal pregnancies was 17.2%, while the 
colonisation in high risk pregnancy was 20% [23]. The data 
obtained in the present study indicate a further increase 
in the incidence of GBS colonisation in the population of 
pregnant patients.
Our study has several limitations. First, we investigate 
the implementation of the recommendation only in a popu-
lation of patients admitted to the single IIIrd level perinatal 
center, which is a referral hospital for all highly complicated 
pregnancy in the Lesser Poland region. Even though there 
were no significant differences in our study population in 
maternal comorbidity, there is a risk that our group repre-
sents part of the general population of pregnant women 
that were especially monitored during pregnancy, because 
of their high risk status. On the other hand the fact that the 
patients included in the study were from different parts of 
the region provide a high diversity. Secondly, because the 
antenatal screening is carried out in the out-patient services, 
we do not have the data on the quality of the conducted 
screening test and their results, thus our paper does not 
focus at evaluating the effectiveness of the screening pro-
grammes.
CONCLUSIONS
Screening for syphilis and HBV place our studied popu-
lation among countries with highest prevalence of con-
ducting such screening, on the other hand RV screening 
place its among countries with lowest prevalence. There is 
an increasing trend in conducting HIV screening but there 
are still reports of MTCT which are an examples of insuf-
ficient coverage of the screening. Screening for HCV and 
toxoplasmosis are, in the authors opinion, at satisfactory 
level. It is worth to acknowledge that Poland is one of a few 
European countries conducting such screening in general 
population of pregnant women. The screening for GBS is 
insufficient which, in our population, could possibly result 
in excessive use of intrapartum antibiotic prophylaxis.
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